Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q20746326> ?p ?o }
- Q20746326 subject Q13289876.
- Q20746326 subject Q6403525.
- Q20746326 subject Q7013781.
- Q20746326 subject Q7025150.
- Q20746326 subject Q7130203.
- Q20746326 abstract "Study 329 was a clinical trial conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating depressed teenagers. Marketed as Paxil and Seroxat (among other names), paroxetine had been released in 1991 by the British pharmaceutical company SmithKline Beecham, known since 2000 as GlaxoSmithKline (GSK). The drug made $11.6 billion between 1997 and 2006.Led by Martin Keller, then professor of psychiatry at Brown University, study 329 became controversial when it was discovered that the article which reported the trial results – published in 2001 in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) – had downplayed the trial's negative findings and had been ghostwritten by a PR firm hired by SmithKline Beecham. The controversy led to several lawsuits and strengthened calls for drug companies to disclose all their clinical research data. New Scientist wrote in 2015: "You may never have heard of it, but Study 329 changed medicine."The study, which compared paroxetine with imipramine, a tricyclic antidepressant marketed as Tofranil, failed to show efficacy for paroxetine in adolescent depression, something SmithKline Beecham acknowledged internally in 1998. In addition there were more examples of suicidal thinking and behaviour in the group taking paroxetine. Although the article included these negative results, it did not account for them in its conclusion. On the contrary, it concluded that paroxetine is "generally well tolerated and effective for major depression in adolescents." The company relied on the article to promote paroxetine for off-label use in teenagers.In 2003 Britain's Medicines and Healthcare Products Regulatory Agency (MHRA) analysed study 329 and other GSK studies of paroxetine. It concluded that there was no evidence of paroxetine's efficacy and a clear increase in suicidal behaviour in teenagers using it. The following month the MHRA and US Food and Drug Administration (FDA) advised doctors not to prescribe paroxetine to the under-18s. The MRHA launched a criminal inquiry into GSK's conduct, but announced in 2008 that there would be no charges. In 2004 New York State Attorney Eliot Spitzer sued GSK for having withheld the data. In 2012 the US Justice Department fined the company $3 billion, including a sum for withholding data on paroxetine, unlawfully promoting it for the under-18s, and preparing a misleading article on study 329.The JAACAP article on study 329 was never retracted. The journal's editors say the negative findings are included in a table, and that therefore there are no grounds to withdraw the article. In September 2015 the BMJ published a re-analysis of study 329's data. This concluded that neither paroxetine nor imipramine had differed in efficacy in treating depression from placebo (an inert pill), that the paroxetine group had experienced more suicidal ideation and behaviour, and that the imipramine group had experienced more cardiovascular problems.".
- Q20746326 thumbnail Paxil,_June_2003.jpg?width=300.
- Q20746326 wikiPageExternalLink 12-civ-842.html.
- Q20746326 wikiPageExternalLink glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html.
- Q20746326 wikiPageExternalLink dida.library.ucsf.edu.
- Q20746326 wikiPageExternalLink asu38h10.
- Q20746326 wikiPageExternalLink buu38h10.
- Q20746326 wikiPageExternalLink cvu38h10.
- Q20746326 wikiPageExternalLink duu38h10.
- Q20746326 wikiPageExternalLink epu38h10.
- Q20746326 wikiPageExternalLink oqu38h10.
- Q20746326 wikiPageExternalLink otu38h10.
- Q20746326 wikiPageExternalLink ssu38h10.
- Q20746326 wikiPageExternalLink tnu38h10.
- Q20746326 wikiPageExternalLink uru38h10.
- Q20746326 wikiPageExternalLink vsu38h10.
- Q20746326 wikiPageExternalLink wnu38h10.
- Q20746326 wikiPageExternalLink 6291947.stm.
- Q20746326 wikiPageExternalLink nyagglaxo60204cmp.pdf.
- Q20746326 wikiPageExternalLink gw-attachment-a.pdf.
- Q20746326 wikiPageExternalLink Driven%20to%20Settle.pdf.
- Q20746326 wikiPageExternalLink con014162.pdf.
- Q20746326 wikiPageExternalLink con014155.pdf.
- Q20746326 wikiPageExternalLink con014157.pdf.
- Q20746326 wikiPageExternalLink con017904.pdf.
- Q20746326 wikiPageExternalLink Clinical_trials_and_drug_promotion_Selective_reporting_of_study_329.
- Q20746326 wikiPageExternalLink 653825.
- Q20746326 wikiPageExternalLink 761720.
- Q20746326 wikiPageExternalLink bmj.h4320.
- Q20746326 wikiPageExternalLink doshinov16.ww1_default.pdf.
- Q20746326 wikiPageExternalLink kellers-findings-on-paxil-disputed-by-doctors-fda.
- Q20746326 wikiPageExternalLink controversial-paxil-paper-still-fire-13-years-later.
- Q20746326 wikiPageExternalLink ucm096273.htm.
- Q20746326 wikiPageExternalLink ucm088676.pdf.
- Q20746326 wikiPageExternalLink Protocol329.pdf.
- Q20746326 wikiPageExternalLink Dulcan.pdf.
- Q20746326 wikiPageExternalLink hsin2010-01.
- Q20746326 wikiPageExternalLink 1P2-8578572.html.
- Q20746326 wikiPageExternalLink abstract.
- Q20746326 wikiPageExternalLink abstract.
- Q20746326 wikiPageExternalLink abstract.
- Q20746326 wikiPageExternalLink abstract.
- Q20746326 wikiPageExternalLink abstract.
- Q20746326 wikiPageExternalLink abstract.
- Q20746326 wikiPageExternalLink 20800711.
- Q20746326 wikiPageExternalLink 27720271.
- Q20746326 wikiPageExternalLink complaint-ex1.pdf.
- Q20746326 wikiPageExternalLink complaint-ex2.pdf.
- Q20746326 wikiPageExternalLink us-complaint.pdf.
- Q20746326 wikiPageExternalLink PMC3031939.
- Q20746326 wikiPageExternalLink glaxosmithkline-fined-bribing-doctors-pharmaceuticals.
- Q20746326 wikiPageExternalLink science.research.
- Q20746326 wikiPageExternalLink sally-laden-sti-deposition-20070315.pdf.
- Q20746326 wikiPageWikiLink Q1105202.
- Q20746326 wikiPageWikiLink Q1141363.
- Q20746326 wikiPageWikiLink Q11675.
- Q20746326 wikiPageWikiLink Q119697.
- Q20746326 wikiPageWikiLink Q1247810.
- Q20746326 wikiPageWikiLink Q13289876.
- Q20746326 wikiPageWikiLink Q1436668.
- Q20746326 wikiPageWikiLink Q1470970.
- Q20746326 wikiPageWikiLink Q1550789.
- Q20746326 wikiPageWikiLink Q1553390.
- Q20746326 wikiPageWikiLink Q15574.
- Q20746326 wikiPageWikiLink Q1641007.
- Q20746326 wikiPageWikiLink Q16619888.
- Q20746326 wikiPageWikiLink Q178190.
- Q20746326 wikiPageWikiLink Q18121649.
- Q20746326 wikiPageWikiLink Q1916302.
- Q20746326 wikiPageWikiLink Q203994.
- Q20746326 wikiPageWikiLink Q204711.
- Q20746326 wikiPageWikiLink Q206921.
- Q20746326 wikiPageWikiLink Q211067.
- Q20746326 wikiPageWikiLink Q212322.
- Q20746326 wikiPageWikiLink Q230624.
- Q20746326 wikiPageWikiLink Q2359937.
- Q20746326 wikiPageWikiLink Q247489.
- Q20746326 wikiPageWikiLink Q2585693.
- Q20746326 wikiPageWikiLink Q269829.
- Q20746326 wikiPageWikiLink Q281928.
- Q20746326 wikiPageWikiLink Q2984214.
- Q20746326 wikiPageWikiLink Q3001111.
- Q20746326 wikiPageWikiLink Q30612.
- Q20746326 wikiPageWikiLink Q3064815.
- Q20746326 wikiPageWikiLink Q334477.
- Q20746326 wikiPageWikiLink Q3508789.
- Q20746326 wikiPageWikiLink Q4040482.
- Q20746326 wikiPageWikiLink Q408471.
- Q20746326 wikiPageWikiLink Q42844.
- Q20746326 wikiPageWikiLink Q446142.
- Q20746326 wikiPageWikiLink Q466524.
- Q20746326 wikiPageWikiLink Q4727019.
- Q20746326 wikiPageWikiLink Q4840402.
- Q20746326 wikiPageWikiLink Q4879610.
- Q20746326 wikiPageWikiLink Q49114.